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Abstract
The signaling pathway(s) andmolecular target(s) for 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a tumor vascular-
disrupting agent in late stages of clinical development, are still undefined. As an approach toward identifying po-
tential targets for DMXAA, a tritiated azido-analog of DMXAA was used to probe for cellular binding proteins. More
than 20 cytosolic proteins from murine splenocytes, RAW 264.7 cells, and the HECPP immortalized endothelial cells
were photoaffinity-labeled. Although no protein domain, fold, or binding site for a specific ligand was found to be
shared by all the candidate proteins, essentially all were noted to be oxidizable proteins, implicating a role for redox
signaling in the action of DMXAA. Consistent with this hypothesis, DMXAA caused an increase in concentrations of
reactive oxygen species (ROS) in RAW 264.7 cells during the first 2 hours. This increase in ROSwas suppressed in the
presence of the antioxidant, N -acetyl-L-cysteine, which also suppressed DMXAA-induced cytokine production in
the RAW 264.7 cells with no effects on cell viability. Short interfering RNA (siRNA)–mediated knockdown of one of
the photoaffinity-labeled proteins, superoxide dismutase 1, an ROS scavenger, resulted in an increase in tumor ne-
crosis factor-α production by RAW 264.7 cells in response to DMXAA compared with negative or positive controls
transfected with nontargeting or lamin A/C–targeting siRNA molecules, respectively. The results from these lines of
study all suggest that redox signaling plays a central role in cytokine induction by DMXAA.
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Introduction
A number of low-molecular tumor vascular-disrupting agents are in late
clinical evaluation. Most of these agents, including the combretastatins,
taxanes, and vinca alkaloids, have disruption of normal tubulin polymer-
ization in endothelial cells as their primary mode of action [1]. Tubulin
does not seem to be a primary target for 5,6-dimethylxanthenone-4-
acetic acid (DMXAA), a small molecule that has both vascular-disrupting
activity and cytokine modulatory activity. DMXAA was synthesized
at the Auckland Cancer Society Research Centre [2] as a derivative of
flavone acetic acid (FAA), a flavonoid initially synthesized by Lyonnaise
Industrielle Pharmaceutique (LIPHA, Lyon, France) as part of their anti-
inflammatory program [3]. When FAA was tested by the National Can-
cer Institute, Bethesda, MD, it showed curative properties against a
number of transplantable murine tumors that were resistant to current
chemotherapies [4]. A hallmark activity of DMXAA and of FAA is the
rapid onset of hemorrhagic necrosis of the implanted tumors [5], result-
ing from vascular collapse [6], caused by the induction of apoptosis
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selectively in tumor vascular endothelial cells [7]. After the initial di-
rect antivascular effects, a large panel of cytokines are produced [8,9],
leading to a cascade of secondary host antitumor responses. Tumor
necrosis factor-α (TNF-α), itself a potent vascular-disrupting agent
[10], is suggested to amplify and prolong the direct antivascular ef-
fects of DMXAA and FAA [11,12], whereas the production of type
1 interferons (IFNs) [13] has been attributed to systemic increases in
tumor-specific CD8+ T lymphocytes [14]. More recently, the major
influx of neutrophils into tumors after DMXAA treatment was sug-
gested to be linked to the production of chemokines that included
IFN-γ-inducible protein 10, RANTES, macrophage inflammatory
protein-1(MIP-1), and monocyte chemoattractant protein-1 [8,15].
The molecular mechanism of cytokine induction by DMXAA is
not fully understood, although there is strong evidence for the in-
volvement of the nuclear factor (NF) κB pathway [16–18], as well
as the TANK-binding kinase 1 (TBK1)–interferon (IFN) regulatory
factor 3 (IRF-3) signaling axis [13]. Previous studies from our labo-
ratory using tritiated-DMXAA indicated that the compound diffused
rapidly into cells [18], but specific binding to any cellular proteins
could not be determined because of the low affinity of binding of the
compound. To overcome this problem, photoactivatable azido-analogs
of DMXAA were synthesized in an approach to photoaffinity label po-
tential target proteins [19]. Azido substitution at the 5– or 6– position
of the xanthenone ring produced analogs capable of inducing NF-κB
activation and cytokine production in cultured splenocytes and in-
ducing hemorrhagic necrosis of tumors in mice [19]. Those studies
indicated that the azido-analogs had the same profile of activities as
DMXAA and were therefore likely to have the same target(s). Covalent
bonds formed between the azido-compound and the interacting pro-
teins after photoactivation were predicted to overcome the problems of
the reversible low-affinity binding that occur with DMXAA and its
target(s). The receptors for a number of drugs including verapamil
[20] and paclitaxel [21] were successfully located using a photoaffinity
labeling approach. We report here studies using a tritiated azido-XAA
analog to photoaffinity label potential DMXAA-binding proteins.
More than 20 oxidizable proteins were labeled, leading to the hypoth-
esis that DMXAA may be acting through modulation of redox signal-
ing. Subsequent studies measuring concentrations of reactive oxygen
species (ROS) in cells and the effect of the antioxidant N -acetyl-L-
cysteine (NAC) on DMXAA-induced cytokine production support
this hypothesis.
Materials and Methods
Drugs and Reagents
DMXAAwas synthesized as the sodium salt at the Auckland Cancer
Society Research Centre [2] and dissolved in α-minimal essential me-
dium (α-MEM). 5-Azidoxanthenone-4-acetic acid (5-AzXAA) was
also synthesized at the center [19] and was dissolved in acetonitrile.
For photoaffinity labeling experiments, 5-AzXAA was custom radio-
labeled with tritium by AmBios Labs, Inc (Newington, CT) to display
a specific activity of 0.1 Ci/mmol. NAC (Sigma-Aldrich, Inc, St Louis,
MO) was dissolved in α-MEM.
Preparation of Cell Lysates
Murine RAW 264.7 macrophage-like cell line was maintained in
α-MEM supplemented with 10% (vol./vol.) fetal calf serum (FCS),
100 U/ml penicillin-G, and 100 μg/ml streptomycin sulfate at 37°C
in a humidified atmosphere of 5% CO2/air. The murine HECPP
endothelial cell line [22] was maintained in M199 medium supple-
mented with FCS (10%) and antibiotics. Murine splenocytes were
obtained from C57BL/6 mice after cervical dislocation. Spleen cells
were collected, and red blood cells were removed by osmotic lysis.
All cells were lysed with potassium phosphate buffer (8.02 mM
K2HPO4 and 1.98 mM KH2PO4, pH 7.4) in the presence of 0.5%
Nonidet-P40 (Roche Product Ltd, Auckland, New Zealand) and pro-
tease inhibitor cocktail from Sigma-Aldrich. Protein concentrations in
the lysates were determined by the Bradford assay [23]. Aliquots were
stored at −80°C until use.
Photoaffinity Labeling and Gel Electrophoresis
Cell lysates (150 μg) were incubated with 1.5 μg of [3H]-5-AzXAA
for 30 minutes on ice and UV-irradiated for 10 minutes (Stratlinker
1800; Stratagene, La Jolla, CA). The samples were then precipitated
using 2D Clean-up Kit (Amersham Biosciences, Piscataway, NJ) ac-
cording to the manufacturer’s instructions. The resulting protein pel-
lets were resuspended in 125 μl of rehydration buffer (9.8 M urea,
2% wt./vol. CHAPS, 0.5% vol./vol. ampholyte, pH 3-10 NL,
0.002% wt./vol. bromophenol blue, 2.8 mg/ml dithiothreitol [DTT]
in H2O) and subjected to two-dimensional PAGE using 7-cm isoelec-
tric focusing (IEF) strips containing an immobilized nonlinear pH gra-
dient ranging from pH 3 to 10 (Immobiline DryStrips pH 3-10 NL;
Figure 1. (A) SDS-PAGE gel of RAW 264.7 proteins incubated with
[3H]-5-AzXAA without UV treatment (lane 2), UV-treated (lane 3), pre-
incubated for 30 minutes with 10, 100, and 500-fold excess cold
DMXAA (lanes 4, 5 and 6 respectively), and preincubated with 10-
and 100-fold excess cold 5-AzXAA before UV treatment (lanes 7 and
8). (B) Autoradiograph of the gel showing radioactive protein bands
(0.45 μg of [3H]-5-AzXAA was used for 45 μg of proteins and 30 μg
of protein was loaded per lane).
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GE Healthcare Bio-Sciences, Uppsala, Sweden). After overnight gel re-
hydration, IEF was carried out at 20°C with a current limit of 50 μA
per strip using the Ettan IPGphor IEF System (Amersham Biosciences,
Uppsala, Sweden). The focused IEF strips were equilibrated in 2.5 ml of
equilibration buffer (50 mM Tris-HCl, pH 8.8, 6 M urea, 30% wt./vol.
glycerol, 2% wt./vol. SDS, and 0.002% wt./vol. bromophenol blue)
containing 10 mg/ml DTT, followed by alkylation in 2.5 ml of equili-
bration buffer containing 25 mg/ml iodoacetamide for 15 minutes each.
Equilibrated IEF strips were loaded onto 12% SDS–polyacrylamide
gels, and electrophoresis was performed in a Mini PROTEAN 3 cell
(Bio-Rad Laboratories, Hercules, CA) for 1.5 hours at 120 V. Two-
dimensional gels were stained with Coomassie Blue and soaked in Am-
plify Fluorographic Solution (Amersham Biosciences, Buckinghamshire,
England) for 30 minutes before transferring onto 3-mm filter paper,
and vacuum-dried. The dried amplify-treated gels were exposed to
autoradiographic film (Kodak BioMax XAR Scientific Imaging Film;
CarestreamHealth, Paris, France) at −80°C for 8 weeks. After autoradi-
ography, films were developed and overlaid on the dried Coomassie
Blue–stained gels to locate radiolabeled protein spots.
In-gel Digestion and Mass Spectrometry for
Protein Identification
Protein spots that had been radiolabeled were excised from fresh
two-dimensional gels. Gel pieces were destained in 0.1 M ammonium
bicarbonate/50% acetonitrile (45 minutes at 37°C), dehydrated in
100% acetonitrile, dried in a vacuum centrifuge for 5 minutes, and
rehydrated in 50 μl of 20 mM DTT/0.1 M ammonium bicarbonate
for 30 minutes at 56°C. After another dehydration step in 100% aceto-
nitrile, gel pieces were incubated with 50 μl of 55 mM iodoacetamide/
0.1 M ammonium bicarbonate for 15 minutes at room temperature in
the dark. Subsequently, the gel pieces were washed with 0.1 M ammo-
nium bicarbonate, followed by a dehydration step (100% acetonitrile),
and another wash with milli-Q water. After a final dehydration step
Figure 2. The autoradiograph (left) and the Coomassie Blue–stained two-dimensional gel (right) of lysates from murine splenocytes (A),
RAW264.7 cells (B), or HECPP endothelial cells (C), photoreacted with [3H]-5-AzXAA with protein spots that matched the radiolabeled
spots from the autoradiograph encircled.
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Table 1. Proteins in Murine Cellular Lysates Photoaffinity Labeled with 5-AzXAA.
Protein Spot* MW (kDa) pI Mascot Score† SwissProt Accession Number
(A) Spleen cell lysates
Proteins with known role in cytokine production
S100A9/Calgranulin B/MRP14 1 13.0 6.73 80 P31725
Cyclophilin A 2 18.0 7.88 187 P17742
Superoxide dismutase 3 16.0 6.03 38 P08228
Protein disulfide isomerase A3 precursor 16 57.0 5.98 193 P11598
Cytoskeletal proteins
β-Actin 4 42.0 5.29 155 Q6ZWM3
β-Tubulin 5 50.1 4.78 273 P68372
Tropomyosin α chain 6 32.9 4.68 206 P58771
Proteins that alter cytoskeleton dynamics
Rho GDP-dissociation inhibitor 1 7 23.3 5.12 113 P31725
Rho GDP-dissociation inhibitor 2 8 22.8 4.97 76 P17742
Cofilin-1 9 18.6 8.26 47 Q99PT1
Profilin-1 10 15.0 8.50 142 P18760
Coronin-1A 11 51.5 6.05 123 P62962
Miscellaneous proteins
Hemoglobin α-chain 12 15.0 8.08 41 P01942
Hemoglobin β-chain 13 15.7 7.26 95 P02088
Albumin 14 71.2 5.82 817 P07724
SH3 domain-binding glutamic acid-rich-like
protein 3
15 10.5 5.02 39 Q91VW3
Chloride intracellular channel protein 1 17 27.2 5.09 50 Q921Q5
(B) RAW 264.7 cell lysates
Proteins with known role in cytokine production
Macrophage migration inhibitory factor 22 12.7 6.90 70 P34884
Thioredoxin 1 18 12.0 4.80 79 P10639
Peroxiredoxin 1 16 22.4 8.26 94 P35700
60 kDa heat shock protein, mitochondrial 3 61.1 5.91 207 P63038
Protein disulfide isomerase A6 precursor 5 48.5 5.00 237 Q922R8
Superoxide dismutase [Mn], mitochondrial 16 24.8 8.8 43 P09671
Chaperones/stress proteins
Stress-70 protein, mitochondrial 4 73.8 5.91 338 P38647
Prostaglandin E synthase 3, cytosolic 17 19.0 4.36 89 Q9R0Q7
Glycolytic enzymes
Glyceraldehyde-3-phosphate dehydrogenase 110,11,12 36.1 8.44 60 P16858
Aldose reductase 7 36.1 6.71 120 P45376
Triosephosphate isomerase 13,14 27.0 6.90 55 P17751
L-Lactate dehydrogenase A chain 12 36.1 8.44 98 P06151
Cytoskeletal proteins
β-Actin 6 42.1 5.29 87 P60710
α-Tubulin 2 50.6 4.96 224 P68373
β-Tubulin 1 50.2 4.79 287 P68372
Vimentin 2 53.7 5.06 234 P20151
Miscellaneous proteins
Inositol monophosphatase 8 30.8 5.08 63 O55023
26S protease regulatory subunit 6B 5 47.4 5.18 55 P54775
Chloride intracellular channel protein 1 9 27.3 5.09 95 Q9Z1Q5
(C) HECPP cell lysates
Proteins with known role in cytokine production
Cyclophilin A 19 18.0 7.88 163 P17742
Thioredoxin 1 13 12.0 4.80 82 P10639
Peroxiredoxin 1 17 22.4 8.26 94 P35700
60 kDa heat shock protein, mitochondrial 2 61.1 5.91 297 P63038
Protein disulfide isomerase A1 precursor 4 57.5 4.79 356 P09103
Macrophage migration inhibitory factor 21 12.7 6.9 70 P34884
Chaperones/stress proteins
Prostaglandin E synthase 3, cytosolic 12 19.0 4.36 89 Q9R0Q7
Calreticulin 7 48.1 4.33 96 P14211
Glycolytic enzymes
Glyceraldehyde-3-phosphate dehydrogenase 14 36.1 8.44 76 P16858
Triosephosphate isomerase 15,16 27.0 6.90 48 P17751
Cytoskeletal proteins
α-Tubulin 3 50.6 4.96 359 P68373
β-Tubulin 6 50.1 4.78 527 P68372
β-Actin 5 42.0 5.29 198 Q6ZWM3
Vimentin 3 53.7 5.06 69 P20151
Proteins that alter cytoskeleton dynamics
Rho GDP-dissociation inhibitor 1 9 23.3 5.12 109 P31725
Miscellaneous proteins
Albumin 1 71.2 5.82 64 P07724
ATP synthase β chain 6 56.2 5.15 134 P56480
Nucleophosmin 11 32.7 4.62 138 Q61937
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with 100% acetonitrile, the gel pieces were vacuum-dried for 5 min-
utes. The dried gel pieces were left to absorb 15 μl of trypsin solution
(50 ng/μl trypsin [sequencing grade; Promega, Madison, WI], 0.1 M
ammonium bicarbonate, 10% acetonitrile) for 10 minutes, after which
30 μl of 0.1 M Tris-HCl (pH 9.2)/10% acetonitrile was added, and
left overnight at 37°C. The supernatants were collected the following
day, and the peptides were extracted by two incubations in 150 μl of
0.1% trifluoroacetic acid/60% acetonitrile at 37°C for 30 minutes
each. The peptide extracts were reduced in volume to 1 to 2 μl by
vacuum centrifugation. Fifteen microliters of solvent A (0.1% acetic ac-
id/0.005% heptafluorobutyric acid) was added, and samples were pro-
cessed using a high-performance liquid chromatography system
coupled to an ion trap mass spectrometer (Agilent 1100 Series LC/
MSD Trap System; Agilent Technologies, Boeblingen, Germany). A
0.5 × 150-mm Zorbax SB C18 column (Agilent Technologies) was
pre-equilibrated with solvent A and kept at a constant temperature
of 2°C, onto which 8 μl of peptide samples was injected. Peptides
were eluted off the column at a flow rate of 12 μl/min using a linear
gradient from 90% solvent A (0.1% acetic acid, 0.005% heptafluoro-
butyric acid in water) and 10% solvent B (0.1% acetic acid, 0.005%
heptafluorobutyric acid, 80% acetonitrile in water) 70% solvent B for
45 minutes. The eluted peptides were directly fed into the electrospray
ionize of the mass spectrometer, with a spray voltage of 3.5 kV. The
electrospray interface was set in positive mode, the nebulizer gas was
set at 12 psi, and the drying gas (nitrogen) was delivered at a flow rate
of 4.4 L/min at a temperature of 325°C. Ionmass spectra were collected
in the range of 200 to 2000 m/z with a threshold of 15,000. The LC/
MSD Trap 5.2 software (DataAnalysis version 3.2; Bruker Daltonik,
Agilent Technologies) was used to identify compounds for each ion
mass spectrum. The resulting data were entered into the Mascot MS/
MS Ion Search Engine [24] and compared with spectra in the SwissProt
database (www.expasy.ch/sprot).
Measurement of Intracellular ROS
Intracellular ROS concentrations were determined by oxidation of
2′,7′-dichlorodihydrofluorescein. RAW 264.7 cells (106 cells/well)
cultured in 24-well plates were incubated for different periods with
DMXAA (10 μg/ml). The cells were washed and incubated in the
dark for 20 minutes in PBS containing 0.5% FCS (vol./vol.) and
H2DCF diacetate (Sigma-Aldrich). After another wash, the cells were
resuspended in saline. The mean fluorescence intensity (excitation,
488 nm; emission, 515-540 nm) was measured using flow cytometry
(FACScan Flow Cytometer; BD Bioscience, San Diego, CA).
Effects of NAC on DMXAA Activity
RAW 264.7 cells were seeded in triplicate at 106 cells/well in flat-
bottomed 96-well plates and preincubated with NAC (1-20 mM) for
1 hour. DMXAA (10 μg/ml final concentration) was then added,
and ROS was measured after 2 hours of incubation at 37°C. Culture
supernatants were collected 8 hours after the addition of DMXAA
and assayed using ELISA cytokine kits (OptEIA murine IL-6 and
murine TNF-α; BD Biosciences) or with a multiplex cytokine kit
(catalog no. MCYTO-70K; Linco Research, St Charles, MO) and a
Luminex 100 instrument (Luminex Corporation, Austin, TX). Viabil-
ity of the cells was determined using the sulforhodamine assay [25].
Each treatment was assayed in triplicate, and results were expressed
as mean ± SEM. Data between two groups were compared using un-
paired Student t test or ANOVA if multiple comparisons were made
and were considered significant when the P value was ≤.05.
RNA Interference of SOD1
A pool of four predesigned small interfering RNA (siRNA) mole-
cules (“SmartPool”) targeting murine SOD1 were purchased from
Dharmacon, Inc (Thermo Fisher Scientific, Inc, Lafayette, CT), to-
gether with the positive control siRNA molecules targeting lamin A/C,
and the negative control nontargeting siRNA molecule no. 2. SiRNA
molecules were introduced into cells at 40 nM using Lipofectamine
2000 (Invitrogen, Carlsbad, CA). RAW 264.7 cells (5 × 105/well) were
seeded onto the preformed transfection complexes in six-well plates in
OPTIMEM medium (Invitrogen) without serum. At 4 hours after
transfection, α-MEM supplemented with 20% FCS was added to each
well, and the cells were allowed to grow. At 48 hours after transfection,
the cells were treated with DMXAA (10 μg/ml) for 4 hours, after
which the supernatant was harvested for determination of TNF-α con-
centrations using ELISA, whereas the cells were washed in ice-cold
PBS and their proteins were extracted using RIPA buffer containing
1 × Halt protease cocktail inhibitor (Thermo Scientific, Rockford, IL).
The lysates were used for immunoblot analysis to assess the degree of
knockdown of the target protein. Samples (25 μg protein/well) were
electrophoresed using precast NuPAGE Novex Bis-Tris gel (Invitrogen)
and transferred to a nitrocellulose membrane that was blocked in PBS
containing 0.5% Tween 20 (PBS-T) and 5% nonfat dried milk powder.
Membranes were incubated overnight at 4°C with rabbit anti-SOD1
primary antibodies (Santa Cruz, San Diego, CA) diluted at 1:2500
and then for 1 hour at room temperature with HRS-conjugated sec-
ondary antibodies (Santa Cruz) diluted at 1:10,000 in PBS-T contain-
ing 5% milk powder. Signals were detected using SuperSignal West
Pico Chemiluminescent substrate (Pierce Thermo Scientific, Rockford,
IL), and images were captured on a Fujifilm LAS 3000 imaging sys-
tem (Fujifilm, Tokyo, Japan). The blots were stripped in Restore West-
ern Blot Stripping Buffer (Pierce Thermo Scientific) before reblocking
in PBS-T containing 5% nonfat dried milk powder for determina-
tion of loading using a mouse monoclonal antibody to actin (Milli-
pore, Billerica, MA).
Table 1. (continued )
Protein Spot* MW (kDa) pI Mascot Score† SwissProt Accession Number
Proteasome subunit α6 10 27.8 6.34 234 Q9QUM9
SH3 domain-binding glutamic acid-rich-like
protein 3
13 10.5 5.02 45 Q91VW3
*Spots as in Figure 2A (splenocytes), Figure 2B (RAW 264.7 cells), or Figure 2C (HECPP cells); spots 15, 19, 20, and 21 (Figure 2B; RAW 264.7 cells) and spots 8, 18, 20, 22, 23, and 24 (Figure 2C ;
HECPP cells) could not be identified.
†Mascot score of 30 or greater indicates identity or extensive homology (P < .05).
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Results
Specificity of Labeling with 5-AzXAA
The specificity of the photoaffinity labeling with [3H]-5-AzXAA
was examined using competitive binding studies with cold DMXAA
or cold 5-AzXAA (Figure 1). Cytosolic protein extracts from RAW
264.7 cells were preincubated with up to 500-fold excess concentra-
tions of cold 5-AzXAA or cold DMXAA before the addition of [3H]-
5-AzXAA. The extracts were then exposed to UV irradiation and
then analyzed by SDS-PAGE and autoradiography. The intensity
of the radiolabeling was markedly decreased in the presence of
100- and 500-fold excess cold DMXAA (Figure 1B, lanes 5 and 6 )
when compared with the cytosolic protein extracts that were irradi-
ated without competitor (lane 3) and was completely blocked by 10-
and 100-fold excess cold 5-AzXAA (lanes 7 and 8).
Photoaffinity Labeling of Cytosolic Proteins
Cytosolic proteins from murine splenocytes and RAW 264.7
macrophage-like cells, used previously for studying cytokine induction
[8,13], and the HECPP endothelial cells, used previously for studying
apoptosis induction by DMXAA [7], were photoaffinity-labeled with
[3H]-5-AzXAA and resolved by two-dimensional PAGE. The two-
dimensional gels were exposed to radiographic film, after which the
radiolabeled protein spots were located by overlaying the autoradio-
graph onto the respective two-dimensional gel. The autoradiograph
and the corresponding Coomassie Blue–stained gel from a represen-
tative experiment with murine splenocytes, RAW 264.7 cells, or
HECPP cells are shown in Figure 2, A, B, and C , respectively. Each
autoradiograph (Figure 2, left) shows a number of darkened spots that
could be matched with protein spots on the Coomassie Blue–stained
two-dimensional gel (Figure 2, right). Protein spots that were radio-
labeled were excised for identification using mass spectrometry and
Mascot Search against spectra in SwissProt database. The proteins
identified corresponding to each experiment in Figure 2 are listed
in Table 1.
The separation of proteins was not influenced by incubation with
[3H]-5-AzXAA or by UV irradiation. Coomassie Blue–stained con-
trol two-dimensional gels of protein samples that had not been ex-
posed to [3H]-5-AzXAA or irradiation (Figure W1A), treated with
UV-light only (Figure W1B), or incubated with [3H]-5-AzXAA with-
out photoactivation (Figure W1C ) all showed a similar pattern of dis-
tribution of protein spots.
Table 2. Oxidizable Proteins Photoaffinity-Labeled with 5-AzXAA.
Protein Murine RAW 264.7 Murine Splenocytes Murine HECPP Oxidative Thiol Modifications*
α-Tubulin • • • D
β-Tubulin • • G, D
β-Actin • • • G, D
40S Ribosomal protein 5A • –
60 kDa heat shock protein, mitochondrial • • G
Heat shock cognate 71 kDa protein • G
Albumin • • • G, D
Alcohol dehydrogenase [NADP+] • –
Aldose reductase • • G
Annexin A1/2 • G
ATP synthase α chain • –
Calreticulin • D
Cathepsin B • G
Chloride intracellular channel protein 1 • • D
Cofilin-1A • G
Coronin-1A • G or D
Cyclophilin A • • G
Elongation factor-1 • G
Glyceraldehyde-3-phosphate dehydrogenase • • G, D
Hsc70-interaction protein • • • –
Inorganic pyrophosphatase • • G
Inositol monophosphatase • –
L-Lactate dehydrogenase A chain • • G, D
Macrophage migration inhibitory factor • G
Nucleophosmin • G
Peroxiredoxin-1 • • G, D
Phosphoglycerate mutase 1 • G or D
Profilin-1A • G
Prostaglandin E synthase 3 • • –
Proteasome subunit α • • –
Protein disulfide isomerase A6 • • • G
Rho GDP-dissociation inhibitor 1/2 • • G
S100A9 • G
SH3 domain-binding glutamic acid-rich-like protein 3 • • • –
Stress-70 protein, mitochondrial • • • G
Superoxide dismutase [Cu/Zn] • D
Superoxide dismutase [Mn] • D
Thioredoxin 1 • • • G
Triosephosphate isomerase • • G, D
Tropomyosin α chain • • G, D
Vimentin • • G
*Denotes sensitivity to oxidation as determined by oxidative modification by glutathionylation (G) or protein disulfide bond formation (D) of cysteine residues.
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A minimum of three independent experiments was carried out
with each cell type. A list of the identified proteins compiled from
all the experiments for each cell type is presented in Table 2. Spots 12
and 13 from Figure 2A, identified as hemoglobin α and hemoglo-
bin β, respectively, were not included in the final list because they
most likely represent contaminants from red blood cells in the orig-
inal spleen suspension and were not consistently detected in repeat
experiments. A total of 24, 18, and 30 labeled proteins were identi-
fied for RAW 264.7 cells, splenocytes, and HECPP cells, respectively
(Table 2). Of these, eight proteins (thioredoxin 1, stress-70 protein,
SH3 domain-binding glutamic acid–rich-like protein-3, protein di-
sulfide isomerase A3/6, Hsc70-interaction protein, albumin, β-actin,
and α-tubulin) were detected from lysates from all three cell types
(Table 2), although albumin is likely a contaminant from tissue
culture. Almost all of the photoaffinity-labeled proteins have been
reported to be oxidizable, either by glutathionylation and/or by
forming disulfide bonds at one of their cysteine residues in response
to oxidative stress [26–36].
Modulation of Cellular ROS Concentrations by DMXAA and
Its Effects on Cytokine Production
The observation that oxidizable proteins were preferentially labeled
using 5-AzXAA led us to investigate whether modulation of redox sig-
naling was involved in DMXAA-mediated cytokine production. We
measured DMXAA-induced changes in intracellular concentrations
of ROS in RAW 264.7 cells. Intracellular concentrations of ROS in-
creased during the first 2 hours after the addition of DMXAA in three
independent experiments (Figure 3A). Preincubation with the anti-
oxidant NAC decreased background concentrations of ROS and re-
duced DMXAA-induced ROS concentrations (Figure 3B). We next
tested the ability of NAC to modulate DMXAA-induced TNF-α
and IL-6 production in RAW 264.7 cells. At the concentrations tested,
NAC had no effects on cell viability but reduced the production of
both TNF-α and IL-6 induced with DMXAA in a dose-dependent
manner (Figure 3C ). Using a 32-plex cytokine assay, 10 cytokines
(G-CSF, IL-6, IFN-γ-inducible protein 10, keratinocyte chemoattrac-
tant, monocyte chemoattractant protein-1, MIP-1α, MIP-1β, MIP-2,
RANTES, and TNF-α) from the panel were found to be induced by
DMXAA in the RAW 264.7 cells. Supernatants from cultures pre-
incubated with NAC before the addition of DMXAA had lower con-
centrations of all 10 cytokines (Figure 3D). NAC alone did not induce
cytokines (Figure 3D). Concentration of cytokines in the entire panel
assayed is presented in Table 3.
SiRNA Knockdown of SOD1
RNA interference was used to knock down the expression of
SOD1, a protein with antioxidant functions that was photoaffinity-
labeled in both RAW 264.7 cell and spleen cell extracts (Table 2),
to examine the effect of reducing its expression on TNF-α induction
by DMXAA. Because SOD1 is a scavenger of ROS, we hypothesized
Figure 3. (A) Accumulation of ROS after the addition of DMXAA (10 μg/ml) in cultures of RAW 264.7 cells in three independent experi-
ments. (B) Effect of 1 hour of preincubation with NAC (20 mM) on ROS concentrations in RAW 264.7 cells untreated or after treatment
with DMXAA (10 μg/ml) for 2 hours. Mean ± SEM of triplicate cultures. (C) Effect of 1 hour of pretreatment with various concentrations
of NAC on cell viability (•), TNF-α (○), and IL-6 production (▾) in cultures of RAW 264.7 cells stimulated 8 hours with DMXAA (10 μg/ml).
Mean ± SEM of triplicate cultures. *Statistical significance compared with cultures treated with DMXAA only and no NAC (P < .05, one
way ANOVA). (D) Cytokine levels in RAW 264.7 cell cultures without treatment (black bar), preincubated with NAC (1 hour, 20 mM) (open
bars), or cultured 8 hours with DMXAA (10 μg/ml) without preincubation with NAC (hatched bars) or with preincubation with NAC
(striped bars). Mean ± SEM of triplicate cultures. *Statistical significance compared with untreated cultures. #Statistical difference
compared with cultures treated with DMXAA but without NAC preincubation. ▪Value above maximum detection limit.
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that knockdown of SOD1 would attenuate ROS scavenging activity
in the cells, resulting in higher ROS concentrations and increased
TNF-α production. Consistent with the hypothesis, in four indepen-
dent experiments, DMXAA-induced TNF-α production in cultures
of SOD1 knockdown cells was significantly higher than that of the
control cultures of cells transfected with the nontargeting negative con-
trol siRNA molecules (P = .003, P < .001, P < .001, and P = .003) or
cells transfected with the lamin A/C–positive control molecules (P =
.007, P = .007, P = .002, and P = .003). In addition, in all experi-
ments, RAW 264.7 cells transfected with the negative nontargeting
control siRNA molecule or the positive control siRNA molecule tar-
geting lamin A/C showed similar levels of TNF-α production as those
treated with Lipofectamine 2000 alone, and each was lower than that
of untransfected cells. TNF-α levels from a representative experiment
are shown in Figure 4A, together with the Western blot of SOD1 in
the protein extracts from the various treatment groups (Figure 4B).
Discussion
The present study sought to identify the cellular target protein(s) of
DMXAA, a vascular-disrupting agent that is currently undergoing
phase 3 clinical evaluation, but whose mode of action is still only
partly understood. To this end, a photoaffinity labeling approach
was taken using tritiated 5-AzXAA as the photoactive ligand. The
specificity of this method was confirmed in competitive binding ex-
periments with splenocyte extracts [19] and with RAW 264.7 cellular
lysates (Figure 1).
A total of 24, 18, and 30 proteins were successfully identified in this
study as being photoaffinity-labeled with [3H]-5-AzXAA in cytosolic
extracts from RAW 264.7 cells, murine splenocytes, and HECPP cells,
respectively. In terms of their broad physiological function, the labeled
cytosolic proteins included those with a known role in cytokine pro-
duction, cytoskeletal proteins, proteins that alter cytoskeleton dynam-
ics, chaperones, glycolytic enzymes, and proteins with miscellaneous
functions (Table 1). This large number of potential DMXAA target
proteins was unexpected, particularly because the two-dimensional
gel system used was capable of resolving only the more abundant
cellular proteins. Essentially all the labeled proteins shared a common
feature, namely, oxidizable thiols. This conclusion was derived from
literature reports showing that those proteins could undergo thiol-
specific oxidative modification through glutathionylation and/or di-
sulfide bridge formation, on exposure of the cell to oxidative stress
[26–36], and led us to consider that DMXAA may interact with target
proteins through their accessible and oxidizable thiol groups, for ex-
ample, cysteine residues. Determination of whether the photoaffinity
label is indeed linked to peptide fragments containing cysteine residues
is planned. Of note, the cytoskeletal proteins actin and tubulin were
among the eight proteins that were photoaffinity-labeled in all cell
types, and treatment of endothelial cells with DMXAA has been
shown to cause partial dissolution of the actin cytoskeleton, which
may be part of its antivascular action [37].
Although the results here suggest that 5-AzXAA with UV irradia-
tion, covalently binds to cellular proteins in vitro, it is not yet known
whether such adducts are formed with this class of compounds under
physiological conditions in vivo. Adduct formation between proteins
and xenobiotics, including taxol [21], 1,4-benzoquinone, and 1,4-
naphthoquinone [38] or endogenous compounds, such as dopamine
or its metabolite dihydroxyphenylacetic acid [39], is widely reported
in the literature. Covalent binding of DMXAA to target proteins con-
ceivably may also occur. In this regard, DMXAA and its predecessor
FAA have been proposed to undergo intramolecular protonation to
form pyrylium-type cationic salts, which would be expected to dis-
play a high affinity for electrons and be capable of electron transfer
[40]. Furthermore, oxidation of FAA generates carbon radical species
after decarboxylation [41], which could also lead to covalent bond
formation with proteins. DMXAA also decarboxylates in solution
when exposed to sunlight [42]. Agents capable of electron transfer
are able to transmit an electron to oxygen and generate a wide range
of ROS. The formation of ROS in RAW 264.7 cells in response to
DMXAA (Figure 3B) supports the idea that DMXAA might indeed
be capable of electron transfer. The acetic acid group at positions 4
and 8, respectively, is essential for the formation of DMXAA- and
FAA-derived pyrylium salts [40] and for the generation of radicals
after a decarboxylation pathway [41]. Interestingly, structure-activity
studies of xanthone and flavone analogs showed an absolute require-
ment for the acetic acid group at those positions for analogs with anti-
tumor activity [2,3]. It is not known at this point whether oxidation
of DMXAA can occur spontaneously under physiological conditions
or is an enzymatically catalyzed process.
The discovery that oxidizable proteins were preferentially labeled in
all three cell types (Table 2) suggests that DMXAA might act through
the modulation of redox signaling. Many key effects of DMXAA are
inducible by redox signaling: reorganization of the actin cytoskeleton
and stimulation of apoptosis in endothelial cells [43], activation of
Table 3. Cytokine Production in RAW264.7 Cells Untreated, NAC Only, or DMXAA-Treated
with or without Previous Incubation with NAC.
Cytokine Concentration (pg/ml)*
Untreated NAC DMXAA DMXAA + NAC
Eotaxin 6 ± 0 6 ± 0 9 ± 1 6 ± 0
G-CSF 7 ± 1 6 ± 0 392 ± 79 40 ± 24
GM-CSF 6 ± 0 6 ± 0 8 ± 1 8 ± 1
IFN-γ 6 ± 0 6 ± 0 9 ± 0 6 ± 0
IL-10 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-12(p40) 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-12(p70) 6 ± 0 6 ± 0 19 ± 1 10 ± 1
IL-13 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-15 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-17 6 ± 0 6 ± 0 26 ± 3 14 ± 3
IL-1α 6 ± 0 6 ± 0 27 ± 8 7 ± 0
IL-1β 19 ± 2 44 ± 4 27 ± 5 51 ± 6
IL-2 7 ± 1 7 ± 1 12 ± 0 8 ± 1
IL-3 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-4 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-5 6 ± 0 6 ± 0 27 ± 3 11 ± 1
IL-6 6 ± 0 6 ± 0 1002 ± 129 309 ± 117
IL-7 6 ± 0 6 ± 0 6 ± 0 6 ± 0
IL-9 126 ± 19 70 ± 16 146 ± 2 92 ± 11
IP-10 17 ± 1 6 ± 0 7609 ± 904 2636 ± 402
KC 6 ± 0 6 ± 0 311 ± 23 20 ± 4
LIF 6 ± 0 6 ± 0 11 ± 1 8 ± 1
LIX 6 ± 0 6 ± 0 287 ± 43 121 ± 44
M-CSF 6 ± 0 6 ± 0 10 ± 1 8 ± 2
MCP-1 546 ± 42 141 ± 11 3781 ± 145 1149 ± 152
MIG 6 ± 0 6 ± 0 11 ± 4 6 ± 0
MIP-1α 161 ± 7 113 ± 3 25,171 ± 0 8766 ± 1897
MIP-1β 75 ± 5 29 ± 7 19,834 ± 5337 8183 ± 418
MIP-2 300 ± 16 315 ± 26 4078 ± 347 2779 ± 651
RANTES 8 ± 2 6 ± 0 698 ± 13 39 ± 3
TNF-α 8 ± 1 6 ± 0 3052 ± 1494 431 ± 98
VEGF 313 ± 19 6 ± 0 355 ± 25 6 ± 0
*Mean ± SEM of three cultures per treatment group.
GM-CSF indicates granulocyte/macrophage colony-stimulating factor; MIG, monokine induced
by IFN-γ; VEGF, vascular endothelial growth factor.
762 Oxidizable Proteins and Redox Signaling in DMXAA Brauer et al. Neoplasia Vol. 12, No. 9, 2010
NF-κB [44], and TNF-α production [45]. DMXAA induced an in-
crease in the generation of ROS in RAW 264.7 cells, and preincuba-
tion with the antioxidant NAC reversed both ROS generation and
induction of a number of cytokines, including TNF-α by DMXAA
(Figure 3), consistent with the hypothesis that ROS play a central
role in its molecular action. SiRNA knockdown of SOD1, a direct
scavenger of ROS, increased TNF-α production in response to
DMXAA (Figure 4), again consistent with the involvement of ROS
in DMXAA-induced cytokine production.
The suggestion that DMXAA induces cytokine production through
modulation of redox signaling does not rule out that activation of clas-
sic signaling pathway(s) after binding to yet unidentified receptor(s)
also occurs. In many inflammatory responses, cytokine production
can occur through both ROS-dependent and ROS-independent path-
ways, and lipopolysaccharide (LPS)-mediated TNF-α production
would be a prime example [45]. The ROS-dependent pathway of
NF-κB–mediated transcriptional activation of the TNF gene after ex-
posure to LPS in RAW 264.7 cells was shown to be responsible for
approximately 50% of the TNF-α produced [45].
Synergistic TNF-α production by human peripheral blood leuko-
cytes and murine splenocytes in culture in response to DMXAA has
been shown with the addition of a costimulator [46,47]. Agents that
were effective as costimulators with DMXAA for TNF-α production
included LPS, IL-1, phorbol myristate acetate, and okadaic acid at
suboptimal concentrations that did not, by themselves, induce the cy-
tokine [46,47]. Interestingly, all these compounds have been reported
to promote the production of ROS [44,48,49]. Approaches that in-
crease cellular ROS concentrations might provide beneficial strategies
for improving the activity of DMXAA. Of note, the phase 3 evalua-
tion of DMXAA is in combination with carboplatin and paclitaxel
(ATTRACT-1 and ATTRACT-2; Novartis, Basel, Switzerland). Both
carboplatin [50] and paclitaxel have been demonstrated to induce the
generation of ROS, with the accumulation of hydrogen peroxide being
crucial for paclitaxel-induced cancer cell death in vivo [51].
In summary, the studies here support a role of redox signaling in the
action of DMXAA. Whether the observed increase in ROS is a direct
or indirect effect of the compound and the identification of the en-
zymes and mechanisms involved in generating a radical species from
DMXAA under physiological conditions require further investigation.
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Figure W1. Coomassie Blue–stained two-dimensional gels of
HECPP cellular lysateswithout exposure to radiation or [3H]-5-AzXAA
(A), treatedwith UV radiation but no or [3H]-5-AzXAA (B), or incubated
with or [3H]-5-AzXAA but without radiation (C).
